Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health

REFERENCES

• Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology 2004;122:564–72.
   PubMed Web of Science ®Google Scholar
• Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. American Journal of Ophthalmology 2010;150:315–24e1.
   PubMed Web of Science ®Google Scholar
• Singer MA, Awh CC, Sadda S, et al. HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119:1175–83.
   PubMed Web of Science ®Google Scholar
• Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2011;364:1897–908.
   Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537–48.
   PubMed Web of Science ®Google Scholar
• Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: An analysis of the 100% 2008 medicare fee-for-service part B claims file. American Journal of Ophthalmology 2011;151:887–95 e1.
   PubMed Web of Science ®Google Scholar
• Lad EM, Hammill BG, Qualls LG, Wang F, Cousins SW, Curtis LH. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. American Journal of Ophthalmology 2014;158:537–43 e2.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services, Office of Inspector General. Medicare Payments for Drugs Used to Treat Wet Age-Related Macular Degeneration; Washington, DC: HHS, 2012.
   Google Scholar
• Comparison of Age-Related Macular Degeneration Treatments Trials Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012;119:1388–98.
   PubMed Web of Science ®Google Scholar
• Los M, Roodhart JM, Voest EE. Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. The Oncologist 2007;12:443–50.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surgery, Lasers & Imaging 2005;36:331–5.
   PubMed Web of Science ®Google Scholar
• Whoriskey P, Keating D. An effective eye drug is available for $50, but many doctors choose a $2,000 alternative, Washington Post, 2013 Dec 8.
   Google Scholar
• Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035–47.
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld PJ. Ranibizumab therapy for neovascular age-related macular degeneration. Retin Physician 2004;1:16–22.
   Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2006;355:1419–31.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine 2006;355:1432–44.
   PubMed Web of Science ®Google Scholar
• Harding SP. Neovascular age-related macular degeneration: Decision making and optimal management. Eye 2010;24:497–505.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen. Journal of Molecular Biology 1999;293:865–81.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179–82.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855–9.
   PubMed Web of Science ®Google Scholar
• Chase, M. How Genentech wins at blockbuster drugs: CEO to critics of prices: “Give me a break,” The Wall Street Journal, 2007 June 5.
   Google Scholar
• Levinson DR. Review of Medicare Part B Avastin and Lucentis treatments for Age-Related Macular Degeneration; Washington, DC: Department of Health and Human Services, 2011.
   Google Scholar
• Hutton D, Newman-Casey PA, Tavag M, Zacks D, Stein J. Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period. Health Affairs 2014;33:931–9.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258–67.
   PubMed Web of Science ®Google Scholar
• Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. The British Journal of Ophthalmology 2013;97:266–71.
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 2013;120:2300–9.
   PubMed Web of Science ®Google Scholar
• Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015;122:146–52.
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Decullier E, Souied EH, et al. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: An updated meta-analysis of randomised clinical trials. Graefe’s Archive for Clinical and Experimental Ophthalmology 2014;252:1529–37.
   PubMed Web of Science ®Google Scholar
• Investigators IS, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399–411.
   Google Scholar
• Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. The Cochrane Database of Systematic Reviews 2014;9:CD011230.
   PubMed Web of Science ®Google Scholar
• Goldberg RA, Flynn HW, Jr., Isom RF, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. American Journal of Ophthalmology 2012;153:204–8 e1.
   PubMed Web of Science ®Google Scholar
• Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn’t blind people, people blind people. American Journal of Ophthalmology 2012;153:196–203e1.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Chomsky AS, Sternberg P, Jr. Reducing the risk of endophthalmitis after intravitreous injection. JAMA Ophthalmology 2013;131:674–5.
   PubMed Web of Science ®Google Scholar
• Williams, George. Health care reform 2015, dollars and sense. Comprehensive Ophthalmology Pearls XVIII, Nashville, TN, April 11, 2015.
   Google Scholar
• Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): Modelling cost effectiveness. The British Journal of Ophthalmology 2007;91:1244–6.
   PubMed Web of Science ®Google Scholar
• Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society 2013;111:56–69.
   PubMedGoogle Scholar
• Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Archives of Internal Medicine 2003;163:1637–41.
   Google Scholar
• Jeng KW, Wilgucki J, Halperin S, et al. Retina specialists treating age-related macular degeneration recommend different approaches for patients than they would choose for themselves. Retina 2014;34:1796–801.
   Google Scholar
• Pollack, A. Genentech offers secret rebates for eye drug, The New York Times, 2010 Nov 3.
   Google Scholar
• Kaufman SR. Drugs, doctors, profits, and conflicts of interest: Avastin versus lucentis. The Virtual Mentor 2010;12:955–8.
   PubMedGoogle Scholar
• Spurling GK, Mansfield PR, Montgomery BD, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: A systematic review. PLoS Medicine 2010;7:e1000352.
   PubMed Web of Science ®Google Scholar
• Thomas A, Abrams, R. Paid to promote eye drug, and prescribing it widely, The New York Times, 2014 Dec 14.
   Google Scholar
• Genentech Inc. Genentech statement on CAT trial data published in the New England Journal of Medicine, San Francisco, CA, 28 Apr 11.
   Google Scholar
• Goldstein J. FDA contradicts genentech on eye drug, The Wall Street Journal, 17 June 2008.
   Google Scholar
• Pollack, A. Genentech will restrict eye use of cancer drug, The New York Times, 2007 Oct 11.
   Google Scholar
• Mantone J. Genentech, eye docs make peace on avastin, The Wall Street Journal, 20 Dec 2007.
   Google Scholar
• Genentech, Inc. Lucentis co-pay card. Retrieved from www.lucentiscopaycard.com/web/guest/patient/enrollment-main. 2015.
   Google Scholar
• Ubel PA, Jepson C, Baron J, Hershey JC, Asch DA. The influence of cost-effectiveness information on physicians’ cancer screening recommendations. Social Science & Medicine 2003;56:1727–36.
   PubMed Web of Science ®Google Scholar